Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
2 reports, 1 independent
Updated Sep 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Jefferies, Citigroup, and Leerink Partners issued rating updates and price targets for Phathom Pharmaceuticals.
- Leerink Partners decreased its target price on CVS Health, while BNP Paribas and Wyoming increased their holdings.
- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.
- Leerink partners and Jefferies Financial Group issued ratings for Latigo Biotherapeutics, which also appointed Todd Smith as CEO.